BOSTON SCIENTIFIC CORP

BSX · Large cap · Calculated market cap · $63.3B · as of 2026-09-30

Company Stats

Market Cap: $63.3B; as of Sep 30, 2026
Shares Outstanding: 1.4B
Free Float: 99.8%

Income Statement

Revenue: $20.1B
Operating Income: $3.6B
Net Income: $2.9B
EBITDA: $5.0B
Non-cash Impairment: $46.0M
Revenue Growth, 3Y: 16.5%
FCF Margin, 3Y Avg: 15.5%
FCF Margin, Worst Year: 12.6%

Cash Flow

Free Cash Flow: $3.7B
FCF Yield: 5.8%
Owner FCF Yield: 5.3%

Balance Sheet

Cash & Equivalents: $2.0B

Returns & Capital

SBC, 3Y Avg: $266.0M

Cash Flow by Year

Year	Revenue	FCF	Margin
FY2025	$20.1B	$3.7B	18.2%
FY2024	$16.7B	$2.6B	15.8%
FY2023	$14.2B	$1.8B	12.6%
FY2022	$12.7B	$938.0M	7.4%
FY2021	$11.9B	$1.3B	11.1%

Annual filing data through FY ended December 31, 2025; shares and float as of October 24, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.

Company RSS

Earnings

Oct 28, 2026Boston Scientific Sales Growth Slows to 1.5 Percent Jul 29, 2026Boston Scientific Beats Profit Forecast as Sales Growth Slows

Other Coverage

October 6, 2026 FDA

Boston Scientific Recalls Imager II Angiographic Catheters September 28, 2026 QBook

Stronger demand supports expansion as pricing diverges September 17, 2026 FDA

Boston Scientific Recalls ENROUTE Transcarotid System September 17, 2026 FDA

Boston Scientific Recalls ENROUTE Transcarotid System August 14, 2026 Industry Earnings Roundup

Healthcare Earnings: Demand Surges, Costs Bite Back August 7, 2026 Insider Signal

Insiders Buy Into Boston Scientific Restructuring

The Tip Desk